TuHURA Biosciences (TuHURA Biosciences) Cost of Goods Sold : $0.00 Mil (TTM As of Dec. 2022)

View and export this data going back to 2050. Start your Free Trial

What is TuHURA Biosciences Cost of Goods Sold?

TuHURA Biosciences's cost of goods sold for the six months ended in Dec. 2022 was $0.00 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. TuHURA Biosciences's Gross Margin % for the six months ended in Dec. 2022 was %.

Cost of Goods Sold is also directly linked to Inventory Turnover.

TuHURA Biosciences Cost of Goods Sold Historical Data

The historical data trend for TuHURA Biosciences's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Cost of Goods Sold Chart

TuHURA Biosciences Annual Data

Trend

Dec21

Dec22

Cost of Goods Sold

TuHURA Biosciences Semi-Annual Data
	Dec21	Dec22
Cost of Goods Sold	-	-

TuHURA Biosciences Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cost of Goods Sold for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.

TuHURA Biosciences (NAS:HURA) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

TuHURA Biosciences's Gross Margin % for the six months ended in Dec. 2022 is calculated as:

Gross Margin %	=	(Revenue	-	Cost of Goods Sold)	/	Revenue
	=	(0	-	0)	/	0
	=	%

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

TuHURA Biosciences's Inventory Turnover for the six months ended in Dec. 2022 is calculated as:

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.

TuHURA Biosciences Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.

TuHURA Biosciences (TuHURA Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Cost of Goods Sold

Comparable Companies

Traded in Other Exchanges

N/A

Address

10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612

Website

TuHURA Biosciences Inc is a clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies. The company's lead personalized cancer vaccine candidate, IFx-Hu2.0, is designed to prime the activation of the immune system to target and attack tumor cells by making them look like bacteria. Through an intratumoral injection of a gene coding for emm55, an immunogenic bacterial protein that is then expressed on the surface of tumor cells, the immune system is activated, providing a potent, multivalent systemic response against all neoantigens in a patient's tumor.

TuHURA Biosciences (TuHURA Biosciences) Headlines

No Headlines